{"denoms":[{"counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"86"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"4"},{"groupId":"BG011","value":"3"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"2"},{"groupId":"BG014","value":"3"},{"groupId":"BG015","value":"137"}],"units":"Participants"}],"groups":[{"description":"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA.\n\nTreatment Group A included solid tumors and lymphoma","id":"BG000","title":"Part1/Treatment Group A : 8mg QD INCB057643"},{"description":"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA.\n\nTreatment Group A included solid tumors and lymphoma","id":"BG001","title":"Part1/Treatment Group A : 12mg QD INCB057643"},{"description":"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA.\n\nTreatment Group A included solid tumors and lymphoma","id":"BG002","title":"Part1/Treatment Group A : 16mg QD INCB057643"},{"description":"Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group B (TGB), based on protocol-specific criteria. Treatment Group B included any acute leukemia, HRMDS, MDS/MPN, or MF","id":"BG003","title":"Part1/Treatment Group B : 8mg QD INCB057643"},{"description":"Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group B (TGB), based on protocol-specific criteria. Treatment Group B included any acute leukemia, HRMDS, MDS/MPN, or MF.","id":"BG004","title":"Part1/Treatment Group B : 12mg QD INCB057643"},{"description":"Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group C (TGC), based on protocol-specific criteria. Treatment Group C includes subjects with MM","id":"BG005","title":"Part1/Treatment Group C : 8mg QD INCB057643"},{"description":"Initial cohort dose of INCB054763 monotherapy at the specified RP2D dose selected in Part 1 cohort escalation treatment group A (TGA), based on protocol-specific criteria. Part 2 Treatment Group A expansion included pancreatic adenocarcinoma, castration-resistant prostrate cancer, breast cancer, high grade serious ovarian cancer, glioblastoma multiform, non-hodgkin's lymphoma, ewing's sarcoma, and solid tumor or lymphoma.","id":"BG006","title":"Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort"},{"description":"Initial cohort dose of INCB057463 monotherapy at the specified RP2D dose selected in Part 1 cohort escalation treatment group B (TGB), based on protocol-specific criteria. Part 2 Treatment Group B expansion included pancreatic adenocarcinoma, castration-resistant prostrate cancer, breast cancer, high grade serious ovarian cancer, glioblastoma multiform, non-hodgkin's lymphoma, ewing's sarcoma, and solid tumor or lymphoma.","id":"BG007","title":"Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort"},{"description":"Initial cohort dose of INCB057643 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Gemcitabine) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies where Gemcitabine is relevant","id":"BG008","title":"Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg"},{"description":"Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Paclitaxel) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies.","id":"BG009","title":"Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg"},{"description":"Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Rucaparib) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies.","id":"BG010","title":"Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg"},{"description":"Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Abiraterone + Prednisone) in Castration Resistant Prostrate Cancer","id":"BG011","title":"Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni"},{"description":"Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Ruxolitinib) in Myelofibrosis.","id":"BG012","title":"Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg"},{"description":"Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Azacitidine) in Acute Myeloid Leukemia and Myelodysplastic Syndrome","id":"BG013","title":"Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg"},{"description":"3 participants enrolled in the study and discontinued the study before study drug is administered","id":"BG014","title":"Enrolled But Not Dosed"},{"description":"Total of all reporting groups","id":"BG015","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.21","value":"64.3"},{"groupId":"BG001","spread":"12.26","value":"60.2"},{"groupId":"BG002","spread":"11.44","value":"60.5"},{"groupId":"BG003","spread":"5.81","value":"68.9"},{"groupId":"BG004","spread":"7.33","value":"75.8"},{"comment":"SD is not calculable as there is only 1 participant enrolled in this arm.","groupId":"BG005","spread":"NA","value":"70.0"},{"groupId":"BG006","spread":"13.80","value":"60.6"},{"groupId":"BG007","spread":"10.92","value":"72.6"},{"groupId":"BG008","spread":"0","value":"72.0"},{"groupId":"BG009","spread":"12.73","value":"56.0"},{"groupId":"BG010","spread":"6.16","value":"66.0"},{"groupId":"BG011","spread":"4.04","value":"67.7"},{"groupId":"BG012","spread":"0","value":"75.0"},{"groupId":"BG013","spread":"2.12","value":"76.5"},{"groupId":"BG014","spread":"6.24","value":"66.0"},{"groupId":"BG015","spread":"12.80","value":"63.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"48"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"4"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"1"},{"groupId":"BG015","value":"68"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"38"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"3"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"2"},{"groupId":"BG014","value":"2"},{"groupId":"BG015","value":"69"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"71"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"4"},{"groupId":"BG011","value":"3"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"2"},{"groupId":"BG014","value":"3"},{"groupId":"BG015","value":"111"}]}],"title":"White/Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"10"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"16"}]}],"title":"Black/African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"1"}]}],"title":"American-Indian/Alaska Native"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"1"}]}],"title":"Native Hawaiian/Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"6"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"1"}]}],"title":"Missing"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}]}